Qiagen Submits Second PMA for Therascreen KRAS Companion Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen today said that it has submitted a second Premarket Approval application to the US Food and Drug Administration for its therascreen KRAS RGQ PCR Kit for use a companion diagnostic with metastatic colorectal cancer drug Erbitux (cetuximab).

Erbitux is sold in the US by Bristol-Myers Squibb and Eli Lilly. Outside of the US and Canada, it is sold by Germany's Merck KGaA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.